Pfizer is rolling the dice again on an oral obesity pill.The pharmaceutical giant signed an exclusive global license agreement with YaoPharma, a subsidiary of China’s Fosun Pharma.The deal involves YP05002, an oral small-molecule GLP-1 agonist, with a $150 million upfront payment plus up to $1.935 billion in milestone rewards.This marks…
Donald Trump is preparing to begin a final round of interviews for the next Federal Reserve chair, setting up…
Bitcoin surged to its highest level in three weeks on Tuesday evening, marking what analysts at blockchain intelligence firm…
Global markets opened on Wednesday on a cautious note as investors balanced major corporate developments with heightened macroeconomic uncertainty.…
Efforts to finalise a sweeping trade agreement between the United States and Indonesia are facing renewed uncertainty, with US…
The US shale sector is anticipating a new round of M&A-driven consolidation among small- and medium-sized producers. This trend is…
The Indian subcontinent, long favoured by multinationals for its vast consumer market, is now drawing a fresh wave of…
China’s latest inflation readings point to a recovery that remains uneven, with rising consumer prices offset by a deeper…
Europe is dealing with a full spectrum of political and economic flashpoints today.Musk’s X is in open confrontation with…